- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
November 11, 2024Tommy Du Honored With 2024 Sheila Sonenshine Associate Pro Bono Award
-
December 3, 2024Can You Keep a Secret? Privacy Laws and Civil Litigation
-
December 4, 2024Trust & Estate Litigation in Minnesota
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
November 6, 2024How Recent Patent Damages Precedent May Increase Reasonable Royalty Awards
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
New ANDA Cases
Spring 2012
Case Name |
Date Filed |
Judge |
Drug |
Patent No(s). |
Takeda Pharma. Co. Ltd. v. Mylan, Inc., 12-0024 (S.D.N.Y.) |
Jan. 3, 2012 |
Hon. Denise L. Cote |
Actoplus Met®XR (pioglitazone HCl/metforminHCl extended-release) |
5,965,584 6,099,859 6,166,043 6,172,090 6,495,162 6,790,459 6,866,866 7,785,627 7,919,116 7,959,946 |
Shire LLCv. Sandoz, Inc., 12-0040 (D. Col.) |
Jan. 6, 2012 |
Hon. Marcia S. Krieger |
Intuniv®(quanfacine hydrocholoride extended-release tablet) |
5,854,290 6,287,599 6,811,794 |
Takeda Pharma. Co. Ltd. v. Mylan, Inc., 12-0026 (W.D. Pa.) |
Jan. 6, 2012 |
Hon. Arthur J. Schwab |
Actoplus Met®XR (pioglitazone HCl/metforminHCl extended-release) |
5,965,584 6,099,859 6,166,043 6,172,090 6,495,162 6,790,459 6,866,866 7,785,627 7,919,116 7,959,946 |
Merck Frosst Canada & Co. v. Teva Pharma. USA Inc., 12-0210 (D.N.J.) |
Jan. 11, 2012 |
Hon. Freda L. Wolfson |
Singulair®(montelukast sodium oral granules eq. to 4 ml base/packet) |
8,007,830 |
Meda Pharma. Inc. v. ApotexInc., 12-0361 (D.N.J.) |
Jan. 19, 2012 |
Hon. Peter G. Sheridan |
Astepro®(azelastine hydrochloride nasal spray) |
8,071,073 |
Abbott Labs. v. CadilaHealthcareLtd., 12-0065 (D. Del.) |
Jan. 20, 2012 |
Hon. Sue L. Robinson |
Niaspan®(niacin extended-release tablet) |
6,080,428 |
Spectrum Pharma. Inc. v. Sandoz Inc., 12-0111 (D. Nev.) |
Jan. 20, 2012 |
Hon. Larry R. Hicks |
Fusilev®(levoleucovorin for injection) |
6,500,829 |
Eli Lilly & Co. v. Accord Healthcare, Inc., USA, 12-0086 (S.D. Ind.) |
Jan. 20, 2012 |
Hon. Richard L. Young |
Alimta®(pemetrexed disodium for injection) |
7,772,209 |
Cephalon, Inc. v. MylanPharma.Inc., 12-0073 (D. Del.) |
Jan. 24, 2012 |
Hon. Sue L. Robinson |
Fentora®(fentanyl buccal tablet) |
8,092,832 |
Cephalon, Inc. v. Sandoz, Inc., 12-0074 (D. Del.) |
Jan. 24, 2012 |
Hon. Sue L. Robinson |
Fentora®(fentanyl buccal tablet) |
8,092,832 |
AstraZeneca AB v. TorrentPharma.Ltd., 12-0506 (D.N.J.) |
Jan. 26, 2012 |
Hon. Joel A. Pisano |
Nexium®(esomeprazole magnesium delayed-release capsules) |
5,714,504 5,877,192 6,875,872 |
Valeant Int’l (Barbados) SRL v. SpearPharma., Inc., 12-0043 (M.D. Fla.) |
Jan. 26, 2012 |
Hon. John E. Steele |
Carac®(fluorouracil topical cream 0.5%) |
6,670,335 |
Allergan, Inc. v. Hi-Tech Pharmacal Co., 12-0043 (E.D. Tex.) |
Jan. 27, 2012 |
Hon. Michael H. Schneider |
Lumigan®(bimatoprost ophthalmic solution, 0.01%) |
7,851,504 |
Takeda Pharma. Co., Ltd. v. Sandoz Inc., 12-0446 (N.D. Cal.) |
Jan. 27, 2012 |
Hon. Joseph C. Spero |
Dexilant®(dexlansoprazole delayed-release capsules) |
6,462,058 6,664,276 6,939,971 7,285,668 7,790,755 |
Abbott Labs. v. Sandoz, Inc., 12-0103 (D. Del.) |
Jan. 30, 2012 |
Hon. Sue L. Robinson |
Simcor®(niacin and simvastatin tablets) |
6,080,428 6,469,035 |
Shire LLC v. Mylan Pharma. Inc., 12-0638 (D.N.J.) |
Feb. 2, 2012 |
Hon. Stanley R. Chesler |
Vyvanse®(lisdexamfetamine dimesylate capsule) |
7,105,486 7,223,735 7,655,630 7,659,253 7,659,254 7,662,787 7,671,030 7,671,031 7,674,774 7,678,770 7,678,771 7,687,466 7,687,467 7,718,619 7,723,305 |
Purdue Pharma L.P. v. Sandoz Inc., 12-0897 (S.D.N.Y.) |
Feb. 3, 2012 |
Hon. Sidney H. Stein |
OxyContin®(controlled-release oxycodone) |
6,488,963 7,674,799 7,674,800 7,683,072 7,776,314 |
Senju Pharma. Co., Ltd. v. ApotexInc., 12-0159 (D. Del.) |
Feb. 10, 2012 |
Hon. Sue L. Robinson |
Zymaxid®(gatifloxacin ophthalmic solution 0.5%) |
5,880,283 6,333,045 |
Merck & CIE v. WatsonPharma., Inc., 12-0161 (D. Del.) |
Feb. 10, 2012 |
Hon. Richard G. Andrews |
Beyaz®(drospirenone/ethinyl estradiol/levomefolate calcium tablets and Levomefolate calcium tablets) |
6,441,168 |
Merck & CIE v. WatsonPharma., Inc., 12-0223 (D. Nev.) |
Feb. 13, 2012 |
Hon. Larry R. Hicks |
Beyaz®(drospirenone/ethinyl estradiol/levomefolate calcium tablets and Levomefolate calcium tablets) |
6,441,168 |
Novo Nordisk Inc. v. AurobindoPharmaLtd., 12-1026 (D.N.J.) |
Feb. 16, 2012 |
Hon. Freda L. Wolfson |
Prandin®(repaglinide tablets) |
6,677,358 |
Spectrum Pharma, Inc. v. Innopharma, Inc., 12-0265 (D. Nev.) |
Feb. 17, 2012 |
Hon. Gloria M. Navarro |
Fusilev®(levoleucovorin for injection) |
6,500,829 |
Abbott Labs. v. Hospira, Inc., 12-0234 (D. Del.) |
Feb. 27, 2012 |
Hon. Gregory M. Sleet |
Zemplar®(paricalcitolfor injection) |
5,597,815 |
Abbott Labs. v. AmnealPharma., LLC, 12-0235 (D. Del.) |
Feb. 27, 2012 |
Hon. Sue L. Robinson |
Niaspan®(niacin extended release tablets) |
6,080,428 |
Nautilus Neurosciences, Inc. v. Wockhardt USA LLC, 12-1243 (D.N.J.) |
Feb. 27, 2012 |
Hon. Esther Salas |
Cambia®(diclofenac potassium for oral solution) |
8,097,651 |
Cephalon, Inc. v. MylanPharma.Inc., 12-0247 (D. Del.) |
Feb. 29, 2012 |
Hon. Sue L. Robinson |
Fentora®(fentanyl citrate buccal tablets) |
8,119,158 |
Cephalon, Inc. v. SandozInc., 12-0248 (D. Del.) |
Feb. 29, 2012 |
Hon. Sue L. Robinson |
Fentora®(fentanyl citrate buccal tablets) |
8,119,158 |
Merck Frosst Canada & Co. v. Dr. Reddy’s Labs., Ltd., 12-1324 (D.N.J.) |
Mar. 2, 2012 |
Hon. Freda L. Wolfson |
Singulair®(montelukast sodium oral granules eq. to 4 mg base/packet) |
8,007,830 |
Depomed, Inc. v. Actavis Elizabeth LLC, 12-1358(D.N.J.) |
Mar. 2, 2012 |
Hon. Joel A. Pisano |
Gralise®(gabapentin extended-release tablets) |
6,340,475 6,488,962 6,635,280 6,723,340 7,438,927 7,731,989 |
Abbott Labs. v. Mylan Inc., 12-0257 (D. Del.) |
Mar. 2, 2012 |
Hon. Sue L. Robinson |
Niaspan®(niacin extended-release tablets) |
6,080,428 6,129,930 6,406,715 6,469,035 6,676,967 6,746,691 6,818,229 7,011,848 7,998,506 |
Avanir Pharma., Inc. v. WatsonPharma., Inc., 12-0258 (D. Del.) |
Mar. 2, 2012 |
Hon. Leonard P. Stark |
Nuedexta®(dextromethorphan hydrobromide/quinidine sulfate capsules) |
7,659,282 RE38,115 |
Spectrum Pharma., Inc. v. Innopharma, Inc., 12-0260 (D. Del.) |
Mar. 2, 2012 |
Hon. Christopher J. Burke |
Fusilev®(levoleucovorin) |
6,500,829 |
AstraZeneca AB v. Mylan Labs. Ltd., 12-1378 (D.N.J.) |
Mar. 6, 2012 |
Hon. Joel A. Pisano |
Nexium®(esomeprazole magnesium capsules) |
5,714,504 5,877,192 6,875,872 |
Avanir Pharma., Inc. v. Watson Pharma., Inc., 12-1463 (D.N.J.) |
Mar. 8, 2012 |
Hon. William J. Martini |
Nuedexta®(dextromethorphan hydrobromide/quinidine sulfate capsules) |
7,659,282 RE38,115 |
Genzyme Corp. v. Invagen Pharma., Inc., 12-1164 (E.D.N.Y.) |
Mar. 8, 2012 |
Hon. Jack B. Weinstein |
Renagel®(sevelamer hydrochloride tablets) |
5,667,775 |
AstraZeneca AB v. Mylan Labs.Ltd., 12-0300 (D. Del.) |
Mar. 12, 2012 |
Hon. Mary Pat Thynge |
Nexium®(esomeprazole magnesium capsules) |
5,714,504 5,877,192 6,875,872 |
Genzyme Corp. V. Invagen Pharma., Inc., 12-1819 (S.D.N.Y.) |
Mar. 12, 2012 |
Hon. Jed S. Rakoff |
Renagel®(sevelamer hydrochloride tablets) |
5,667,775 |
Forest Labs., Inc. v. TorrentPharma.Ltd., 12-0305 (D. Del). |
Mar. 13, 2012 |
Hon. Sue L. Robinson |
Bystolic®(nebivolol hydrochloride) |
6,545,040 |
Allergan, Inc. v. Apotex, Inc., 12-0247 (M.D.N.C.) |
Mar. 13, 2012 |
Hon. Catherine C. Eagles |
Latisse®(bimatoprost ophthalmic solution, 0.03%) |
8,038,988 8,101,161 |
Forest Labs., Inc. v. Indchemie Health Specialties Pvt. Ltd., 12-1855 (N.D. Ill.) |
Mar. 14, 2012 |
Hon. Elaine E. Bucklo |
Bystolic®(nebivolol hydrochloride) |
6,545,040 |
United Therapeutics Corp. v. Sandoz, Inc., 12-1617 (D.N.J.) |
Mar. 14, 2012 |
Hon. Peter G. Sheridan |
Remodulin®(treprostinil sodium for injection) |
5,153,222 6,765,117 7,999,007 |
Alkermes Pharma Ireland Ltd. v. Actavis, Inc., 12-0323 (D. Del.) |
Mar. 16, 2012 |
Hon. Sue L. Robinson |
Focalin®XR (dexmethylphenidate hydrochloride capsules) |
6,228,398 6,730,325 |
Abbott Labs. v. Watson, Pharma., Inc., 12-0324 (D. Del.) |
Mar. 16, 2012 |
Hon. Sue L. Robinson |
Niaspan®(niacin extended-release tablet) |
6,080,428 6,469,035 |
Celgene Corp. v. Actavis South Atlantic LLC, 12-1688 (D.N.J.) |
Mar. 16, 2012 |
Hon. Susan D. Wigenton |
Focalin®XR (dexmethylphenidate hydrochloride capsules) |
5,908,850 6,355,656 6,528,530 5,837,284 6,635,284 7,431,944 |
Shire Development LLC v. Osmotica Pharma. Corp., 12-0904 (N.D. Ga.) |
Mar. 16, 2012 |
Hon. Amy Totenberg |
Lialda®(mesalamine delayed-release tablets) |
6,773,720 |
Novartis Pharma.Corp. v. Actavis Group HF., 12-0366 (D. Del.) |
Mar. 21, 2012 |
Hon. Christopher J. Burke |
Exjade®(deferasirox tablets for oral suspension) |
6,465,504 6,596,750 |
Cubist Pharma., Inc. v. Hospira, Inc., 12-0367 (D. Del.) |
Mar. 21, 2012 |
Hon. Gregory M. Sleet |
Cubicin®(daptomycin for injection) |
6,468,967 6,852,689 8,058,238 RE39,071 |
Novartis Pharma.Corp. v. ActavisElizabethLLC, 12-1798 (D.N.J.) |
Mar. 22, 2012 |
Hon. Dennis M. Cavanaugh |
Exjade®(deferasirox tablets for oral suspension) |
6,465,504 6,596,750 |
Allergan, Inc. v. Watson Labs. Inc., 12-0197 (E.D. Tex.) |
Mar. 23, 2012 |
Hon. Michael H. Schneider |
Lumigan®(bimatoprost ophthalmic solution, 0.01%) |
7,851,504 5,688,819 |
Horizon Pharma., Inc. v. Par Pharma. Companies, 12-0393 (D. Del.) |
Mar. 28, 2012 |
Unassigned |
Duexis®(ibuprofren and famotidine) |
8,067,033 |
Eagle Pharma., Inc. v. Sandoz, Inc., 12-1938 (D.N.J.) |
Mar. 30, 2012 |
Hon. Peter G. Sheridan |
Argatroban®(argatroban injectable) |
7,589,106 7,687,516 |
GlaxoSmithKline PLC v. Hikma Pharma.Co., Ltd., 12-1965 (D.N.J.) |
Mar. 30, 2012 |
Hon. Freda L. Wolfson |
Argatroban®(argatroban injectable) |
5,214,052 |
Allergan, Inc. v. Watson Pharma., Inc., 12-0321 (M.D.N.C.) |
Mar. 30, 2012 |
Unassigned |
Latisse®(bimatoprost ophthalmic solution, 0.03%) |
7,351,404 7,388,029 8,038,988 6,403,649 8,017,655 |
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.